Japan-based clinical-stage biopharmaceutical company developing therapies for underactive bladder (UAB)
Japan-based clinical-stage biopharmaceutical company developing therapies for underactive bladder (UAB). Its lead candidate, SFG-02, is a novel acetylcholinesterase inhibitor formulated for transdermal delivery. The company completed a Phase 1 trial in healthy participants and is preparing patient trials in Japan and the United States.